# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $5 price target.
Equillium (NASDAQ:EQ) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.15) by 10...
The Independent Data Monitoring Committee (IDMC) recommended continuation of the clinical trial based on safety assessment and ...
Minimum Bid Price Below $1.00 For 30 Consecutive Days; No Immediate Effect On Listing; Has Until January 15, 2025 To Regain Com...
Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe au...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $5 price target.